持续皮下胰岛素输注联合维格列汀治疗2型脆性糖尿病的临床研究

Clinical application of continuous subcutaneous insulin infusion combined with vildagliptin to patients with type 2 brittle diabetes mellitus

目的:探讨持续皮下胰岛素输注(CSII)联合维格列汀在2型脆性糖尿病患者中的应用效果。方法:选取2型脆性糖尿病患者64例,按照随机数字表法分为对照组和观察组,每组各32例。对照组采用CSII联合安慰剂治疗,观察组采用CSII联合维格列汀治疗。分析两组血压、胰岛素日用量、血糖、血清氧化应激指标及不良反应。结果:治疗3个月后,观察组SBP、DBP、胰岛素日用量、血糖、血糖波动及活性氧(ROS)水平均低于对照组(P<0.05);观察组谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)、总抗氧化能力(T-AOC)水平高于对照组(P<0.05);两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:CSII联合维格列汀治疗2型脆性糖尿病患者,可有效稳定调节血糖,提高治疗效果。

Objective:To investigate the application effect of continuous subcutaneous insulin infusion(CSII)combined with vildagliptin on patients with type 2 brittle diabetes.Methods:A total of 64 patients with type 2 brittle diabetes were selected and randomized into the control group and observation group,each with 32 cases.The control group were treated with CSII combined with placebo,while the observation group were treated with CSII combined with vildagliptin.Then,the blood pressure,daily insulin dosage,blood glucose,serum oxidative stress index and adverse reactions of patients were compared between both groups.Results:After three months of treatment,the systolic blood pressure(SBP),diastolic blood pressure(DBP),daily insulin dosage,blood glucose,reactive oxygen species(ROS)level was lower than that of the control group(P0.05).Conclusion:For patients with type 2 brittle diabetes,the application of CSII combined with vildagliptin can effectively regulate the patients′ blood sugar and improve the therapeutic effect.